Understanding breast cancer risk -- where do we stand in 2005?
- PMID: 15784178
- PMCID: PMC6741339
- DOI: 10.1111/j.1582-4934.2005.tb00350.x
Understanding breast cancer risk -- where do we stand in 2005?
Abstract
Breast cancer is the most frequent cancer in women and represents the second leading cause of cancer death among women (after lung cancer). The etiology of breast cancer is still poorly understood with known breast cancer risk factors explaining only a small proportion of cases. Risk factors that modulate the development of breast cancer discussed in this review include: age, geographic location (country of origin) and socioeconomic status, reproductive events, exogenous hormones, lifestyle risk factors (alcohol, diet, obesity and physical activity), familial history of breast cancer, mammographic density, history of benign breast disease, ionizing radiation, bone density, height, IGF- 1 and prolactin levels, chemopreventive agents. Additionally, we summarized breast cancer risk associated with the following genetic factors: breast cancer susceptibility high-penetrance genes (BRCA1, BRCA2, p53, PTEN, ATM, NBS1 or LKB1) and low-penetrance genes such as cytochrome P450 genes (CYP1A1, CYP2D6, CYP19), glutathione S-transferase family (GSTM1, GSTP1), alcohol and one-carbon metabolism genes (ADH1C and MTHFR), DNA repair genes (XRCC1, XRCC3, ERCC4/XPF) and genes encoding cell signaling molecules (PR, ER, TNFalpha or HSP70). All these factors contribute to a better understanding of breast cancer risk. Nonetheless, in order to evaluate more accurately the overall risk of breast tumorigenesis, novel genetic and phenotypic traits need to be identified.
Similar articles
-
Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.Breast. 2016 Aug;28:136-44. doi: 10.1016/j.breast.2016.05.006. Epub 2016 Jun 16. Breast. 2016. PMID: 27318168 Review.
-
Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.Breast Cancer Res Treat. 2006 Jan;95(1):81-7. doi: 10.1007/s10549-005-9047-1. Epub 2005 Oct 27. Breast Cancer Res Treat. 2006. PMID: 16261400
-
Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.Eur J Surg Oncol. 2015 May;41(5):641-6. doi: 10.1016/j.ejso.2015.01.021. Epub 2015 Feb 17. Eur J Surg Oncol. 2015. PMID: 25736863
-
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.Breast Cancer Res Treat. 2004 Nov;88(2):177-86. doi: 10.1007/s10549-004-0593-8. Breast Cancer Res Treat. 2004. PMID: 15564800
-
Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations.Biol Res. 2017 Oct 6;50(1):35. doi: 10.1186/s40659-017-0139-2. Biol Res. 2017. PMID: 28985766 Free PMC article. Review.
Cited by
-
Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women.PLoS One. 2009 Dec 4;4(12):e8180. doi: 10.1371/journal.pone.0008180. PLoS One. 2009. PMID: 19997605 Free PMC article.
-
The 2017 Network Tools and Applications in Biology (NETTAB) workshop: aims, topics and outcomes.BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):125. doi: 10.1186/s12859-019-2681-0. BMC Bioinformatics. 2019. PMID: 30999855 Free PMC article.
-
Knowledge and Perceptions of Common Breast Cancer Risk Factors in Northern Saudi Arabia.Asian Pac J Cancer Prev. 2017 Oct 26;18(10):2755-2761. doi: 10.22034/APJCP.2017.18.10.2755. Asian Pac J Cancer Prev. 2017. PMID: 29072404 Free PMC article.
-
Capsanthin-Loaded Micelles: Preparation, Characterization and in vitro Evaluation of Cytotoxicity Using MDA-MB-231 Breast Cancer Cell Line.Food Technol Biotechnol. 2022 Sep;60(3):350-360. doi: 10.17113/ftb.60.03.22.7405. Food Technol Biotechnol. 2022. PMID: 36320357 Free PMC article.
-
Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women.Oncol Lett. 2022 Aug 8;24(4):331. doi: 10.3892/ol.2022.13451. eCollection 2022 Oct. Oncol Lett. 2022. PMID: 36039053 Free PMC article.
References
-
- Parkin D. M., International variation, Oncogene, 23: 6329–6340, 2004. - PubMed
-
- Stewart S. L., King J. B., Thompson T. D., Friedman C., Wingo P. A., Cancer mortality surveillance–United States, 1990–2000, MMWR. Surveill. Summ., 53: 1–108, 2004. - PubMed
-
- Jemal A., Thomas A., Murray T., Thun M., Cancer statistics, 2002, CA Cancer. J.Clin., 52: 23–47, 2002. - PubMed
-
- Bray F., Sankila R., Ferlay J., Parkin D. M., Estimates of cancer incidence and mortality in Europe in 1995, Eur. J. Cancer, 38: 99–166, 2002. - PubMed
-
- Edwards B. K., Howe H. L., Ries L. A., Thun M. J., Rosenberg H. M., Yancik R., Wingo P. A., Jemal A., Feigal E. G., Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and againg on U.S. Cancer burden, Cancer, 94: 2766–2792, 2002. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous